Results 111 to 120 of about 55,801 (184)

Dual targeting of solid tumors using cytokine-induced killer cells modified with a CAR anti-tenascin C and a secretable EGFRxCD3 bispecific antibody. [PDF]

open access: yesCancer Immunol Immunother
Zaninelli S   +13 more
europepmc   +1 more source

CAR-T cell immunotherapy in rhabdomyosarcoma. [PDF]

open access: yesJ Transl Med
Safarzadeh Kozani P   +2 more
europepmc   +1 more source

Case Report: Three cases with allogeneic CIK therapy against solid tumors. [PDF]

open access: yesFront Immunol
Li Y   +5 more
europepmc   +1 more source

Development and activity of canine B7-H3-CAR.CIK lymphocytes against sarcomas: preclinical evidence and perspectives for human clinical translation. [PDF]

open access: yesCancer Immunol Immunother
De Maria R   +18 more
europepmc   +1 more source

Tumor-priming CD8<sup>+</sup> natural killer T-like cells as an efficient novel cell therapy for relapsed/refractory multiple myeloma. [PDF]

open access: yesExp Hematol Oncol
Lee J   +13 more
europepmc   +1 more source

The cGAS-STING pathway is a master regulator of OCT4 expression in persistent sarcoma cells and enhances cellular immunotherapy with NK and CIK lymphocytes. [PDF]

open access: yesCancer Immunol Immunother
Giordano G   +19 more
europepmc   +1 more source

The Liver Week 2025 Highlights: Celebrating the 30th Anniversary of the Korean Association for the Study of the Liver. [PDF]

open access: yesClin Mol Hepatol
Chon YE   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy